Graph not available
Graph not available

Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Gujarat Themis Biosyn Ltd Fundamentals

Market Cap
₹ 2940.25 Cr
P/E Ratio (TTM)
49.72
P/B Ratio
14.60
Debt to Equity
0.01
ROE
45.92
EPS (TTM)
8.14
Dividend Yield
0.37 %
Book Value
27.72

Click here to know more about Fundamentals

Gujarat Themis Biosyn Ltd Financials

Gujarat Themis Biosyn Ltd Financials

Gujarat Themis Biosyn Ltd Shareholding Pattern

Held By Mar 2024 Dec 2023 Sep 2023 Jun 2023
Promoters 70.87 % 70.87 % 75.00 % 75.00 %
Retail 22.26 % 23.40 % 21.85 % 22.13 %
Others 5.02 % 4.84 % 3.12 % 2.84 %
FII 1.05 % 0.87 % 0.01 % 0.01 %
Mutual Funds 0.80 % 0.02 % 0.02 % 0.02 %

Promoters

70.87%

Retail

22.26%

Others

5.02%

FII

1.05%

Mutual Funds

0.80%

Promoters

70.87%

Retail

23.40%

Others

4.84%

FII

0.87%

Mutual Funds

0.02%

Promoters

75.00%

Retail

21.85%

Others

3.12%

FII

0.01%

Mutual Funds

0.02%

Promoters

75.00%

Retail

22.13%

Others

2.84%

FII

0.01%

Mutual Funds

0.02%

Delivery and Volume

About Gujarat Themis Biosyn Ltd

Promoted by Kantilal Shah, Gujarat Themis Biosyn Limited was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985. It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is being actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007. Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990. However, problems relating to purity levels, yield and imports put the company in the red and it became a BIFR case in 1990. Subsequently, it was taken over by a group consisting of Lyka Labs, Themis Chemicals, Kopran and Cadila. Also, Yuhan Corporation, South Korea, brought in technology and finance for running GTBL. During 1995-96 the paid-up share capital increased from Rs 11.25 crores to Rs 11.60 crores after allotment of 350,000 Equity shares of Rs 10 each at a premium of Rs 20 per share to the financial institutions by way of conversion of fund interst term loan. During the year installed capacity of rifamysin-S was increased to 90 mtpa and expansion of rifampicin was achieved to the maximum capacity of 120 mtpa. It also commenced operations of its new pharmaceutical division and launched a wide range of anti-tuberculosis products and other antibiotics. The company is constantly identifying new areas for diversification and also capacity expansion of exisiting product in order to further reduction in cost of production and increase in turnover.

Managing Director

1981

Founded

NA

NSE Symbol

GUJTHEMIS

Gujarat Themis Biosyn Ltd Management

NameDesignation
Dinesh S PatelChairman & Non Executive Dir.
Sachin D PatelNon Executive Director
VIJAY GOPI KISHAN AGARWALIndependent Non Exe. Director
Kirandeep MadanIndependent Non Exe. Director
Vikram D SanghviIndependent Non Exe. Director
Siddharth Y KusumgarIndependent Non Exe. Director

Events

Dividend Announcement for Gujarat Themis Biosyn Ltd - Feb 10, 2024

On Feb 10, 2024, shareholders are set to receive a dividend payout, with each share entitling its holder to a dividend of 75.0%. This dividend percentage reflec...

Read More

Gujarat Themis Biosyn Ltd News

Gujarat Themis Biosyn fixes record date for dividend
Record date is 15 July 2024
Gujarat Themis Biosyn to convene AGM
On 23 July 2024
Gujarat Themis Biosyn standalone net profit rises 35.93% in the March 2024 quarter
Sales rise 52.27% to Rs 42.01 crore
Board of Gujarat Themis Biosyn recommends Final Dividend
Of Rs.0.25 per share
Gujarat Themis Biosyn to convene board meeting
On 14 May 2024
Board of Gujarat Themis Biosyn recommends Interim Dividend
Of Rs.0.75 per share
Gujarat Themis Biosyn fixes record date for interim dividend
Record date is 22 February 2024
Gujarat Themis Biosyn standalone net profit rises 32.62% in the December 2023 quarter
Sales rise 37.95% to Rs 38.86 crore
Gujarat Themis Biosyn announces board meeting date
On 10 February 2024
Gujarat Themis Biosyn
Sales down 17%

Similar Stocks

Gujarat Themis Biosyn Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Gujarat Themis Biosyn Ltd shares in BlinkX

Gujarat Themis Biosyn Ltd's P/E ratio is 49.72 times as of January 1, 1970 at 12:00 AM.

Gujarat Themis Biosyn Ltd's most recent financial reports indicate a price-to-book ratio of 14.60, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Gujarat Themis Biosyn Ltd's market is 2,940 Cr as on January 1, 1970 at 12:00 AM.

The current financial records of Gujarat Themis Biosyn Ltd show a 45.92% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

According to Gujarat Themis Biosyn Ltd's most recent financial filings, the company has a total asset value of Crores, which includes current and non-current assets such as inventory, cash, properties, and equipment.

As of the Mar 2024 quarter, the promoter shareholding in Gujarat Themis Biosyn Ltd stands at 70.87%. During the same period, Institutional Investors have shown a slight increase in their holdings, rising from 0.87% to 1.05%.